Assessment of pazopanib-related hypertension, cardiac dysfunction and identification of clinical risk factors for their development

BACKGROUND: Antineoplastic therapy with the tyrosine kinase inhibitor pazopanib in patients with advanced/metastatic renal cell carcinoma (mRCC) has been associated with hypertension (HTN), cardiomyopathy, and cardiac dysrhythmias. We therefore assessed the cardiovascular (CV) risk with pazopanib in...

Descripción completa

Detalles Bibliográficos
Autores principales: Pinkhas, Daniel, Ho, Thai, Smith, Sakima
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5828231/
https://www.ncbi.nlm.nih.gov/pubmed/29497565
http://dx.doi.org/10.1186/s40959-017-0024-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5828231/
https://www.ncbi.nlm.nih.gov/pubmed/29497565
http://dx.doi.org/10.1186/s40959-017-0024-8

Ejemplares similares